Compare · NVO vs TLPH
NVO vs TLPH
Side-by-side comparison of Novo Nordisk A/S (NVO) and Talphera Inc. (TLPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TLPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 3240.1x TLPH ($68.8M).
- TLPH has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for TLPH).
- Company
- Novo Nordisk A/S
- Talphera Inc.
- Price
- -
- -
- Market cap
- $222.81B
- $68.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 5
- 8
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TLPH
- Director Wan Mark A was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Todisco Joseph was granted 5,100 shares, increasing direct ownership by 80% to 11,497 units (SEC Form 4)
- Director Jain Abhinav was granted 5,100 shares, increasing direct ownership by 70% to 12,412 units (SEC Form 4)
- Director Hoffman Stephen J was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Broadfoot Jill Marie was granted 5,100 shares, increasing direct ownership by 60% to 13,647 units (SEC Form 4)
- Director Bozilenko Marina was granted 5,100 shares, increasing direct ownership by 56% to 14,147 units (SEC Form 4)
- Director Adams Adrian was granted 5,100 shares, increasing direct ownership by 29% to 22,709 units (SEC Form 4)
- Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- H.C. Wainwright resumed coverage on Talphera with a new price target
- Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes